Oppenheimer Launches Coverage on DTIL with Outperform Rating – 100%+ Upside Ahead?
Oppenheimer rates DTIL “Outperform” ($20). ARCUS gene editing shows promise in DMD & Hep B with big upside potential.
/ 2 items
Oppenheimer rates DTIL “Outperform” ($20). ARCUS gene editing shows promise in DMD & Hep B with big upside potential.
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, its novel gene editing therapy designed to treat Duchenne muscular dystrophy (DMD).